News | Women's Health | February 23, 2021

Hologic Completes Acquisition of Biotheranostics, Enabling Entry into Growing Oncology Market

Breast Cancer Index added to National Comprehensive Cancer Network guidelines to predict benefit from extended endocrine therapy

 
Breast Cancer Index added to National Comprehensive Cancer Network guidelines to predict benefit from extended endocrine therapy

February 23, 2021 — Hologic, Inc. has completed its previously announced acquisition of molecular oncology leader Biotheranostics, Inc. for approximately $230 million. Biotheranostics develops and markets two highly differentiated molecular diagnostic tests for breast and metastatic cancers – Breast Cancer Index (BCI) and CancerTYPE ID (CTID).

“We are very pleased to complete the acquisition of Biotheranostics and look forward to working with our new colleagues to grow in the large, rapidly expanding oncology space,” said Kevin Thornal, Hologic’s president, Diagnostic Solutions Division. “We are even more excited about the acquisition because last month the National Comprehensive Cancer Network revised its clinical practice guidelines to include Breast Cancer Index as the only gene expression assay to predict benefit from extended endocrine therapy for patients with early-stage hormone-receptor positive breast cancer.”

The National Comprehensive Cancer Network (NCCN) is a not-for-profit alliance of 30 leading cancer centers. Breast Cancer Index is recommended by the NCCN for prediction of which early-stage hormone receptor positive (HR+) breast cancer patients are likely to benefit from extended endocrine therapy. Terminating endocrine therapy in those patients unlikely to benefit may save healthcare dollars and reduce patient exposure to challenging side effects of therapy. Conversely, for patients needing prolonged treatment, Breast Cancer Index can provide the confidence of knowing that the treatment is reducing their risk of recurrence. The BCI test is also included in additional clinical practice guidelines for breast cancer, including those from the American Society for Clinical Oncology (ASCO).

Biotheranostics also developed and markets the CancerTYPE ID test, which provides a molecular diagnosis for patients with uncertain or unknown cancers. In advanced cancer that has metastasized, it can be difficult to determine the tumor type and subtype, information that is needed to optimize treatment selection, particularly with advancements in molecular targeted therapies. CTID compares genomic tumor information to a reference database to find the closest match, enabling physicians to design personalized treatment plans for patients with Unknown Primary Cancer and cases with diagnostic ambiguity.

The BCI and CTID tests are laboratory developed tests that are not required to be cleared or approved by the US Food and Drug Administration.

For more information: www.hologic.com

Related Content

Philips and The Walt Disney Company EMEA announced they are teaming up to test the effects of custom-made animation, including specially-made Disney stories, within Philips Ambient Experience, a solution that integrates architecture, design and enabling technologies, such as dynamic lighting, video projections and sound, to allow patients and staff to personalize their environment to create a relaxing atmosphere

Study will explore the effects and use of animated stories and characters, including Disney favorites, as part of Philips Ambient Experience solution.

News | Magnetic Resonance Imaging (MRI) | March 03, 2021
March 3, 2021 — ...
A single image of a human brain using a magnetic resonance imaging (MRI) machine. Image courtesy of Dr Leon Kaufman. University Of California, San Francisco

A single image of a human brain using a magnetic resonance imaging (MRI) machine. Image courtesy of Dr Leon Kaufman. University Of California, San Francisco

News | Ultrasound Imaging | March 03, 2021
March 3, 2021 — A type of ultrasound scan can detect
Researchers said women who skip even one scheduled mammography screening before a breast cancer diagnosis face a significantly higher risk of dying from the cancer.

Getty Images

News | Mammography | March 03, 2021
March 3, 2021 — Attendance at regular ...
A new study by Rashi Mehta--a researcher with the WVU School of Medicine and Rockefeller Neuroscience Institute--finds that focused ultrasound may induce an immunological healing effect in the brains of Alzheimer's patients.

A new study by Rashi Mehta--a researcher with the WVU School of Medicine and Rockefeller Neuroscience Institute--finds that focused ultrasound may induce an immunological healing effect in the brains of Alzheimer's patients. Image courtesy of Caylie Silveria/West Virginia University

News | Focused Ultrasound Therapy | March 02, 2021
March 2, 2021 — West Virginia University scientists used...
Guerbet announced the launch of OptiProtect 3S, a new range of technical services for its injection solutions. OptiProtect 3S is designed to support imaging centers in the daily use and protection of their injection solutions.
News | Contrast Media Injectors | February 25, 2021
February 25, 2021 — Guerbet announced the launch of ...
Advanced technologies and applications such as point-of-care, pediatrics, dry-magnets, compact MRI and fusion imaging are driving global market
News | Magnetic Resonance Imaging (MRI) | February 24, 2021
February 24, 2021 — Frost & Sullivan's recent analysis, Technological Advancements and Emerging Applications in t
55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned. #COVIDvaccine #COVID19

55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned.

News | Breast Imaging | February 24, 2021